{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T19:11:28Z","timestamp":1648926688271},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,10,23]],"date-time":"2012-10-23T00:00:00Z","timestamp":1350950400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s10384-012-0198-4","type":"journal-article","created":{"date-parts":[[2012,10,22]],"date-time":"2012-10-22T07:12:51Z","timestamp":1350889971000},"page":"95-97","source":"Crossref","is-referenced-by-count":8,"title":["Psoriasis triggered by infliximab in a patient with Beh\u00e7et\u2019s disease"],"prefix":"10.1007","volume":"57","author":[{"given":"Yuko","family":"Kawazoe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunao","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Akino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,10,23]]},"reference":[{"key":"198_CR1","first-page":"667","volume":"29","author":"WJ Shergy","year":"2002","unstructured":"Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol. 2002;29:667\u201377.","journal-title":"J Rheumatol"},{"key":"198_CR2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541\u20139.","journal-title":"Lancet"},{"key":"198_CR3","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1067\/mjd.2002.120472","volume":"46","author":"RE Schopf","year":"2002","unstructured":"Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol. 2002;46:886\u201391.","journal-title":"J Am Acad Dermatol"},{"key":"198_CR4","first-page":"1362","volume":"31","author":"S Ohno","year":"2004","unstructured":"Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362\u20138.","journal-title":"J Rheumatol"},{"key":"198_CR5","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","volume":"140","author":"PP Sfikakis","year":"2004","unstructured":"Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Beh\u00e7et disease. Ann Intern Med. 2004;140:404\u20136.","journal-title":"Ann Intern Med"},{"key":"198_CR6","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/bjo.2009.158840","volume":"94","author":"Y Yamada","year":"2010","unstructured":"Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M. Comparison of infliximab versus cyclosporine during the initial 6-month treatment period in Beh\u00e7et disease. Br J Opthalmol. 2010;94:284\u20138.","journal-title":"Br J Opthalmol"},{"key":"198_CR7","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1136\/bjo.2010.194464","volume":"95","author":"H Keino","year":"2011","unstructured":"Keino H, Okada AA, Watanabe T, Taki W. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet\u2019s disease on infliximab therapy. Br J Ophthalmol. 2011;95:1245\u201350.","journal-title":"Br J Ophthalmol"},{"key":"198_CR8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/09273940802204527","volume":"16","author":"Y Wang","year":"2008","unstructured":"Wang Y, Gaudio PA. Infliximab therapy for 2 patients with Vogt\u2013Koyanagi\u2013Harada syndrome. Ocul Immunol Inflamm. 2008;16:167\u201371.","journal-title":"Ocul Immunol Inflamm"},{"key":"198_CR9","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s10384-010-0859-0","volume":"54","author":"T Ito","year":"2010","unstructured":"Ito T, Sonoda KH, Hijioka K, Fujimoto T, Ishibashi T. Acquired resistance to infliximab against uveitis due to Beh\u00e7et\u2019s disease after one year of administration. Jpn J Ophthalmol. 2010;54:502\u20134.","journal-title":"Jpn J Ophthalmol"},{"key":"198_CR10","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/art.21233","volume":"52","author":"PP Sfikakis","year":"2005","unstructured":"Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy. Arthr Rheum. 2005;52:2513\u20138.","journal-title":"Arthr Rheum"},{"key":"198_CR11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/ard.2005.037424","volume":"65","author":"S Kary","year":"2006","unstructured":"Kary S, Worm M, Audring H, Huscher D, Renelt M, S\u00f6rensen H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis. 2006;65:405\u20137.","journal-title":"Ann Rheum Dis"},{"key":"198_CR12","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1136\/ard.2005.040576","volume":"65","author":"C Matthews","year":"2006","unstructured":"Matthews C, Rogers S, FitzGerald O. Development of new-onset psoriasis while on anti-TNFalpha treatment. Ann Rheum Dis. 2006;65:1529\u201330.","journal-title":"Ann Rheum Dis"},{"key":"198_CR13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","volume":"40","author":"AN Collamer","year":"2010","unstructured":"Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthr Rheum. 2010;40:233\u201340.","journal-title":"Semin Arthr Rheum"},{"key":"198_CR14","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/DAD.0b013e3181cb3ff7","volume":"32","author":"AC Laga","year":"2010","unstructured":"Laga AC, Vleugels RA, Qureshi AA, Velazquez EF. Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-\u03b1 inhibitor therapy. A study of 16 biopsies. Am J Dermatopathol. 2010;32:568\u201373.","journal-title":"Am J Dermatopathol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-012-0198-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10384-012-0198-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-012-0198-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T16:20:36Z","timestamp":1559146836000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10384-012-0198-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,23]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["198"],"URL":"https:\/\/doi.org\/10.1007\/s10384-012-0198-4","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,23]]}}}